2024, Safety and Side effects

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

MAY 25, 2023

The biobank will work in parallel with the MHRA’s Yellow Card website, which is used for reporting adverse events and side effects caused by medicines and medical devices, per the 25 May announcement. According to the press release, the MHRA will be the first drug safety regulator in the world to pilot such a biobank.

Side effects

Side effects Medicine Recruitment Doctors

SXSW 2024 Insights: Why the Greatest Risk a Brand Can Take Is Being Ordinary, Part 1

Eversana Intouch

MARCH 13, 2024

Our team is on the ground at SXSW 2024, and as we navigate through the bustling streets of downtown Austin, Texas — where the magic of immersive brand experiences dress the streets — we can’t help but feel the pulse of innovation surrounding us. The “ugly” aspects, the side effects, and the unpleasant truths are all concealed.

Marketing

Marketing Media Side effects Healthcare

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

NOVEMBER 2, 2023

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Like Stelara, the most serious known side effect of Wezlana is infection.

Food and Drug Administration

Food and Drug Administration FDA Side effects Safety

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

DECEMBER 22, 2023

KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.

Food and Drug Administration

Food and Drug Administration Side effects Safety Food

Encouraging data revealed for schizophrenia long-acting injectables

European Pharmaceutical Review

NOVEMBER 5, 2024

New data presented at Psych Congress 2024 has shown that the olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK demonstrated “significant improvement” in social functioning and quality of life in adults with schizophrenia. This was based on findings from the initial period (up to week 8) of the Phase III SOLARIS trial.

Side effects

Side effects Safety Medical Medicine

New Nkarta data backs up natural killer approach to cancer treatment

pharmaphorum

DECEMBER 5, 2022

In terms of safety, the CAR-NK was associated with some infusion-related side effects that were manageable and resolved quickly, and there were no cases of neurotoxicity, graft versus host disease (GvHD) or cytokine release syndrome (CRS) – all side effects associated with CAR-T therapies.

Side effects

Side effects Safety Patients Leads

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

OCTOBER 17, 2024

In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. Poster Presented at the 2024 AAAAI Annual meeting, DC, US. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA).

Food and Drug Administration

Food and Drug Administration Medicine Consulting Food

What GLP-1 drugs mean for medtech

Clarivate

MAY 1, 2024

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. Device-based treatments for comorbidities associated with obesity will also see an impact. You can register for the webinar here.

Side effects

Side effects Physicians Medical Patients

ANeuroTech shares plans for major depressive disorder pivotal programme

Pharmaceutical Technology

JUNE 16, 2023

This includes the company’s upcoming Phase IIIb trial, but also another Phase III study and a long-term safety trial, said ANeuroTech CEO Eric Buntinx in an interview with Pharmaceutical Technology. The company aims to run an interim analysis of the trial by mid-2024 at the very latest.

Food and Drug Administration

Food and Drug Administration Side effects Safety Recruitment

AUTHENTIC PATIENT VOICE: BOT TO TROT AI Steps Up to Transform Healthcare

PM360

JUNE 24, 2024

As we enter into the age of precision medicine, AI will be a critical tool to determine, with the help of disease knowledge graphs, which indications, associations, contraindications, side effects, genetic markers, drug targets, drug carriers, and interactions to take into account on a case-by-case basis. AI isn’t coming for your job.

Healthcare

Healthcare Healthcare Patients Side effects

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

Food and Drug Administration

Food and Drug Administration Leads Patients Side effects

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

Food and Drug Administration

Food and Drug Administration Leads Patients Side effects

Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. Along with knee osteoarthritis, Grünenthal also plans to test resiniferatoxin in other joints affected by the condition.

Side effects

Side effects Recruitment Patients Safety

Research That Reflects Reality

PM360

OCTOBER 22, 2024

Understanding these effects is critical for payers in determining the true value of a treatment and how it should be positioned in their coverage plans. With older, established drugs, providers can leverage their own experience and insights gained from treating patients with those specific drugs.

Side effects

Side effects Patients Prescription Healthcare

FOCUS ON – Crowdsource/Adherence and Compliance

PM360

OCTOBER 22, 2024

Pharmaceutical companies play a critical role in the design of packaging and labeling for medication, and we are working towards innovative ways to improve and prioritize patient safety, understanding, and adherence. Educational materials for patients, both print out and online, have been used to address common side effects.

Education

Education Side effects Medical Patients

Uncovering the potential of ADCs to target tumours

European Pharmaceutical Review

JULY 18, 2024

1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.

Food and Drug Administration

Food and Drug Administration Engineering Pharmacology Side effects

Overcoming Sales Objections Part 1: Pharma Sales Challenges

Pharmaceutical Representative Training

OCTOBER 9, 2024

They may have valid concerns about the product’s cost, potential side effects, or its suitability for their patients. There are four main categories of objections, known as PETE: Price, Effort, Time, and Effectiveness. 2024, August 27). 2024, September 20). 2024, August 28). link] Jacoby, D.

Sales

Sales Pharma Pharmaceutical Sales Prospecting

NewAmsterdam goes public to advance drug in abandoned class

pharmaphorum

JULY 26, 2022

Merck’s exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following safety or efficacy issues. BROADWAY and BOOKLYN will generate data in 2024, with PREVAIL set to read to in 2026, and if the results are positive will be followed by filings in the US, Europe, China and Japan.

Side effects

Side effects Safety Pharma Patients

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Pharmaceutical Representative Training

JUNE 22, 2024

The pharmaceutical industry is one of the most heavily regulated sectors due to the direct impact of its products on public health and safety. Several factors contribute to the stringent regulatory environment: Patient Safety: Ensuring that the pharmaceutical products are safe and effective is a crucial aspect. link] Reuters.

Sales

Sales Pharmaceutical Ethics Pharmaceutical Sales

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

SEPTEMBER 21, 2023

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted.

Management

Management Manufacturing Sales Competition

Top 5 Emerging Trends in Pharma Industry

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. from 2023 to 2030. from 2023 to 2030.

Pharma

Pharma Medicine Marketing Prospecting

Future of oral small molecule drugs – addressing potential in multiple sclerosis

European Pharmaceutical Review

OCTOBER 3, 2024

It is highly selective and has shown an excellent safety and tolerability profile to date. Advancements in oral small molecule drug development can be attributed to significant technological improvements, particularly in screening methodologies, including AI -driven approaches, which help identify and profile drugs more effectively.

Safety

Safety Pharmaceutical Patients Side effects

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. For this approach, a “3+3” model is used where a study enrolls three patients into a given dose cohort.

FDA

FDA Side effects Pharmacology Patients

Pharma Rep Focus

UK agency pilots biobank to study links between genetics and drug side effects

SXSW 2024 Insights: Why the Greatest Risk a Brand Can Take Is Being Ordinary, Part 1

Webinars

Trending Sources

FDA approves first Stelara biosimilar, Wezlana

Webinars

BMS strikes $14bn deal for Karuna Therapeutics

Encouraging data revealed for schizophrenia long-acting injectables

New Nkarta data backs up natural killer approach to cancer treatment

Innovating allergy drug delivery with a needle-free alternative

What GLP-1 drugs mean for medtech

ANeuroTech shares plans for major depressive disorder pivotal programme

AUTHENTIC PATIENT VOICE: BOT TO TROT AI Steps Up to Transform Healthcare

Developing a new treatment paradigm for chronic kidney disease

Developing a new treatment paradigm for IgAN

Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3

Research That Reflects Reality

FOCUS ON – Crowdsource/Adherence and Compliance

Uncovering the potential of ADCs to target tumours

Overcoming Sales Objections Part 1: Pharma Sales Challenges

NewAmsterdam goes public to advance drug in abandoned class

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

Top 5 Emerging Trends in Pharma Industry

Future of oral small molecule drugs – addressing potential in multiple sclerosis

FDA drug dosage optimisation guidelines signal clinical trial reform

Stay Connected